Aurinia Pharmaceuticals
AUPH
14 hedge funds and large institutions have $20.1M invested in Aurinia Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
269% more capital inflows, than outflows
Capital inflows: $1.22M | Capital outflows: $330K
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0.42% more ownership
Funds ownership: 8.6% → 9.01% (+0.42%)
18% less funds holding
Funds holding: 17 → 14 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
+$1.16M |
| 2 |
Renaissance Technologies
New York
|
+$29.2K |
| 3 |
Redmile Group
San Francisco,
California
|
+$23.8K |
| 4 |
Lombard Odier Asset Management (USA)
New York
|
+$7.69K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$1.91K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$260K |
| 2 |
Goldman Sachs
New York
|
-$61K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3K |
| 5 |
Morgan Stanley
New York
|
-$153 |
AUPH Hedge Fund Activity: Q2 2016 in Review
14 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2016, worth a combined $20.1M — up 2.1% from $19.7M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of AUPH and 0 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Abingworth, adding an estimated $1.16M. The largest seller was Millennium Management, cutting an estimated $260K.
- 14 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2016, down from 17 in Q1 2016.
- Funds reported $20.1M of Aurinia Pharmaceuticals stock for Q2 2016, up 2.1% quarter-over-quarter.
- 0 funds opened new Aurinia Pharmaceuticals positions in Q2 2016 and 3 closed out, a net change of -3 holders.
- The largest Aurinia Pharmaceuticals buyer in Q2 2016 was Abingworth, an estimated $1.16M added.
- The largest Aurinia Pharmaceuticals seller in Q2 2016 was Millennium Management, an estimated $260K sold.
Based on aggregated 13F filings for Q2 2016.